Yang Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yang Liu has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Zhenzhen Ma
2 shared publicationsBin Zhang
1 shared publicationCong Li
Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, China
1 shared publicationFeifei Zhang
1 shared publication- Jiangang Shi
Department of Orthopedic Surgery, Changzheng Hospital, Navy Medical University, Shanghai, China
1 shared publication - Jiarong Ding
Shanghai Changhai Hospital, Navy Medical University, Shanghai 200433, China
1 shared publication
Latest Publications
- Open Access
- 21 October 2025
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 12, 1688702
Explainable machine learning-based prediction of early and mid-term postoperative complications in adolescent tibial fractures
Background: Adolescent tibial fractures commonly lead to postoperative complications. Conventional coagulation markers (PT/APTT/FIB) lack combinatorial risk assessment. We developed an explainable ML model integrating coagulation and clinical features to predict adverse events.Methods: A retrospective cohort of 624 surgical patients (13–18 years) was analyzed. AutoML with Improved Harmony Search Optimization (IHSO) processed features: age, fracture classification, surgery duration, blood loss, and 24 h-postoperative labs (coagulation triad/D-dimer/CRP). Primary outcome: 90-day composite adverse events (DVT/infection/early callus formation disorder/reoperation). SHAP explained predictions.Results: Baseline characteristics were balanced between training and test sets (P > 0.05). The IHSO-optimized algorithm outperformed controls in 91.67% of CEC2022 benchmark functions. AutoML model performance significantly surpassed conventional methods: training set ROC-AUC: 0.9667, test set ROC-AUC: 0.9247 (PR-AUC: 0.8350). Decision curves demonstrated clinical net benefit across 6%–99% risk thresholds. Key feature importance ranked as: age > operative duration > fibrinogen > fracture classification > APTT > CRP > BMI > D-dimer. SHAP analysis revealed: 1) Increasing age significantly attenuates the risk contribution of surgery duration; 2) FIB >4.0 g/L + elevated CRP indicated coagulation-inflammation cascade; 3) AO-C type fractures carried highest risk.Conclusion: This AutoML model, validated through explainability techniques, confirms the core predictive value of age, operative duration, and coagulation-inflammation networks for adolescent tibial fracture risk management. Though requiring prospective validation, the three-tier warning system establishes a stepped framework for individualized intervention. Future studies should advance multicenter collaborations integrating dynamic monitoring indicators to optimize clinical applicability.
- 21 October 2025
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 12, 1688702
Open AccessExplainable machine learning-based prediction of early and mid-term postoperative complications in adolescent tibial fractures
Background: Adolescent tibial fractures commonly lead to postoperative complications. Conventional coagulation markers (PT/APTT/FIB) lack combinatorial risk assessment. We developed an explainable ML model integrating coagulation and clinical features to predict adverse events.Methods: A retrospective cohort of 624 surgical patients (13–18 years) was analyzed. AutoML with Improved Harmony Search Optimization (IHSO) processed features: age, fracture classification, surgery duration, blood loss, and 24 h-postoperative labs (coagulation triad/D-dimer/CRP). Primary outcome: 90-day composite adverse events (DVT/infection/early callus formation disorder/reoperation). SHAP explained predictions.Results: Baseline characteristics were balanced between training and test sets (P > 0.05). The IHSO-optimized algorithm outperformed controls in 91.67% of CEC2022 benchmark functions. AutoML model performance significantly surpassed conventional methods: training set ROC-AUC: 0.9667, test set ROC-AUC: 0.9247 (PR-AUC: 0.8350). Decision curves demonstrated clinical net benefit across 6%–99% risk thresholds. Key feature importance ranked as: age > operative duration > fibrinogen > fracture classification > APTT > CRP > BMI > D-dimer. SHAP analysis revealed: 1) Increasing age significantly attenuates the risk contribution of surgery duration; 2) FIB >4.0 g/L + elevated CRP indicated coagulation-inflammation cascade; 3) AO-C type fractures carried highest risk.Conclusion: This AutoML model, validated through explainability techniques, confirms the core predictive value of age, operative duration, and coagulation-inflammation networks for adolescent tibial fracture risk management. Though requiring prospective validation, the three-tier warning system establishes a stepped framework for individualized intervention. Future studies should advance multicenter collaborations integrating dynamic monitoring indicators to optimize clinical applicability.
- 1 October 2019
- Published by Elsevier in World Neurosurgery
- Vol. 130, e1051-e1060
Metabolic Changes in Serum in the Rat Model of Cauda Equina Injury
- 1 October 2019
- Published by Elsevier in World Neurosurgery
- Vol. 130, e1051-e1060
Metabolic Changes in Serum in the Rat Model of Cauda Equina Injury
- Open Access
- 6 January 2019
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2019, 1-10
Network Pharmacology Integrated Molecular Docking Reveals the Antiosteosarcoma Mechanism of Biochanin A
Background. As the malignant tumor with the highest incidence in teenagers, osteosarcoma has become a major problem in oncology research. In addition to surgical management, the pharmacotherapeutic strategy for osteosarcoma treatment is an attractive way to explore. It has been demonstrated that biochanin A has an antitumor capacity on multiple kinds of solid tumor, including osteosarcoma. But the precise mechanism of biochanin A against osteosarcoma is still needed to be discovered.Objective. To identify the potential therapeutic targets of biochanin A in treating osteosarcoma.Methods. In present study, an integrated approach including network pharmacology and molecular docking technique was conducted, which mainly comprises target prediction, network construction, gene ontology, and pathway enrichment. CCK8 test was employed to evaluate the cell viability of MG63 cells. Western-blot was used to verify the target proteins of biochanin A.Results. Ninety-six and 114 proteins were obtained as the targets of biochanin A and osteosarcoma, respectively. TP53, IGF1, JUN, BGLAP, ATM, MAPK1, ATF3, H2AFX, BAX, CDKN2A, and EGF were identified as the potential targets of biochanin A against osteosarcoma. Based on the western-blot detection, the expression of BGLAP, BAX, and ATF3 in MG63 cell line changed under the treatment of biochanin A.Conclusion. Biochanin A can effectively suppress the proliferation of osteosarcoma and regulate the expression of BGLAP, BAX, and ATF3, which may act as the potential therapeutic targets of osteosarcoma.
- 6 January 2019
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2019, 1-10
Open AccessNetwork Pharmacology Integrated Molecular Docking Reveals the Antiosteosarcoma Mechanism of Biochanin A
Background. As the malignant tumor with the highest incidence in teenagers, osteosarcoma has become a major problem in oncology research. In addition to surgical management, the pharmacotherapeutic strategy for osteosarcoma treatment is an attractive way to explore. It has been demonstrated that biochanin A has an antitumor capacity on multiple kinds of solid tumor, including osteosarcoma. But the precise mechanism of biochanin A against osteosarcoma is still needed to be discovered.Objective. To identify the potential therapeutic targets of biochanin A in treating osteosarcoma.Methods. In present study, an integrated approach including network pharmacology and molecular docking technique was conducted, which mainly comprises target prediction, network construction, gene ontology, and pathway enrichment. CCK8 test was employed to evaluate the cell viability of MG63 cells. Western-blot was used to verify the target proteins of biochanin A.Results. Ninety-six and 114 proteins were obtained as the targets of biochanin A and osteosarcoma, respectively. TP53, IGF1, JUN, BGLAP, ATM, MAPK1, ATF3, H2AFX, BAX, CDKN2A, and EGF were identified as the potential targets of biochanin A against osteosarcoma. Based on the western-blot detection, the expression of BGLAP, BAX, and ATF3 in MG63 cell line changed under the treatment of biochanin A.Conclusion. Biochanin A can effectively suppress the proliferation of osteosarcoma and regulate the expression of BGLAP, BAX, and ATF3, which may act as the potential therapeutic targets of osteosarcoma.